As the specialized pharmaceutical biotechnology landscape continues to evolve, the way products navigate the biosimilars approval pathway has become increasingly complex. In this episode of “Not So Different: a Podcast from The Center for Biosimilars”, senior editor Kelly Davio speaks with Goodwin partner Alexandra Valenti about her experience with biosimilars litigation, the big questions that have already been litigated and what lies ahead for biosimilars as the legal practice matures alongside the industry.
To learn more about the ever-developing world of biosimilars, check out Goodwin’s Big Molecule Watch blog or our recently published Guide to Biosimilars Litigation and Regulation in the US.